Contineum Therapeutics, Inc.
No SEC Form 4 filings for $CTNM in the last 30 days.
See all $CTNM insider activity →Contineum Therapeutics (CTNM) shares rose from lows to a 52-week high. The company's lead drug, PIPE-791, is in a Phase 2 trial for idiopathic pulmonary fibrosis. CTNM's stock has climbed 125% since February 2025, with key catalysts including positive trial results and upcoming conferences. The company also collaborates with Johnson & Johnson on PIPE-307 for depression.
Contineum Therapeutics, Inc. (CTNM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CONTINEUM THERAPEUTICS REPORTS SECOND-QUARTER 2026 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES SAN DIEGO – July 30, 2026 – Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering
Lorrain Daniel S. (Chief Scientific Officer) sold 37,179 shares of Contineum Therapeutics, Inc. (CTNM) at an average of $15.99 ($15.67–$16.24, $0.59M total) across 3 trades over 2026-06-30 to 2026-07-01 under a Rule 10b5-1 trading plan.
Over the past 7 days, alphai's AI scored 1 news story mentioning CTNM (Contineum Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent CTNM coverage spans financial news, insider activity and technology.
Positive trial data and new Phase 2 start suggest near‑term upside.
The filing updates funding visibility and reiterates clinical execution, which can shift near-term risk perception for CTNM’s lead programs.
This is an insider selling disclosure; it may slightly affect sentiment but does not change fundamentals by itself.
Routine corporate governance results; no new operating, financial, or regulatory catalyst beyond confirming board/auditor votes.
Insider selling is a modest, near-term sentiment signal; the presence of a pre-arranged 10b5-1 plan reduces interpretive weight.
alphai scores every news story that mentions CTNM with an AI model for sentiment and relevance, and aggregates insider trades from Contineum Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Contineum Therapeutics (CTNM) shares rose from lows to a 52-week high. The company's lead drug, PIPE-791, is in a Phase 2 trial for idiopathic pulmonary fibrosis. CTNM's stock has climbed 125% since February 2025, with key catalysts including positive trial results and upcoming conferences. The company also collaborates with Johnson & Johnson on PIPE-307 for depression.
2 min readContineum Therapeutics, Inc. (CTNM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CONTINEUM THERAPEUTICS REPORTS SECOND-QUARTER 2026 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES SAN DIEGO – July 30, 2026 – Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering
6 min readLorrain Daniel S. (Chief Scientific Officer) sold 37,179 shares of Contineum Therapeutics, Inc. (CTNM) at an average of $15.99 ($15.67–$16.24, $0.59M total) across 3 trades over 2026-06-30 to 2026-07-01 under a Rule 10b5-1 trading plan.
2 min readContineum Therapeutics, Inc. (CTNM) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. ctnm-20260626 0001855175 FALSE 0001855175 2026-03-05 2026-03-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________ FORM 8-K ________________________________________________________________
2 min readLorrain Daniel S. (Chief Scientific Officer) sold 4,170 shares of Contineum Therapeutics, Inc. (CTNM) at $13.16 on 2026-06-01 under a Rule 10b5-1 trading plan.
2 min readContineum Therapeutics, Inc. announced an inducement grant of a non-qualified stock option to purchase 51,000 shares of Class A common stock to a new non-executive employee. This award, granted on March 12, 2026, is in accordance with Nasdaq Listing Rule 5635(c)(4) and is an inducement material to the employee's new employment. The stock option has an exercise price equal to the closing price on the grant date and vests over four years.
2 min readContineum Therapeutics, Inc. ( NASDAQ:CTNM ) on Thursday shared topline data from its Phase 2 VISTA trial of PIPE-307, an M1 receptor antagonist for relapsing-remitting multiple sclerosis ( RRMS ) .
2 min readThe average of price targets set by Wall Street analysts indicates a potential upside of 235.8% in Contineum Therapeutics, Inc. (CTNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in ...
3 min read
